IL316818A - Tetrahydropyrido[4,3-D]pyrimidine compounds as HPK1 inhibitors - Google Patents

Tetrahydropyrido[4,3-D]pyrimidine compounds as HPK1 inhibitors

Info

Publication number
IL316818A
IL316818A IL316818A IL31681824A IL316818A IL 316818 A IL316818 A IL 316818A IL 316818 A IL316818 A IL 316818A IL 31681824 A IL31681824 A IL 31681824A IL 316818 A IL316818 A IL 316818A
Authority
IL
Israel
Prior art keywords
mmol
pyrido
group
methyl
hydrogen
Prior art date
Application number
IL316818A
Other languages
English (en)
Hebrew (he)
Inventor
Momar Toure
Bin Li
Constantin Neagu
Yanping Wang
Theresa Johnson
Lopez Andrea Unzue
Yufang Xiao
Emily Friis
Maria Dipoto
Satenig Guler
Original Assignee
Merck Patent Gmbh
Momar Toure
Bin Li
Constantin Neagu
Yanping Wang
Theresa Johnson
Lopez Andrea Unzue
Yufang Xiao
Emily Friis
Maria Dipoto
Satenig Guler
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh, Momar Toure, Bin Li, Constantin Neagu, Yanping Wang, Theresa Johnson, Lopez Andrea Unzue, Yufang Xiao, Emily Friis, Maria Dipoto, Satenig Guler filed Critical Merck Patent Gmbh
Publication of IL316818A publication Critical patent/IL316818A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL316818A 2022-05-10 2023-05-04 Tetrahydropyrido[4,3-D]pyrimidine compounds as HPK1 inhibitors IL316818A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263340191P 2022-05-10 2022-05-10
US202263383190P 2022-11-10 2022-11-10
PCT/US2023/066601 WO2023220541A1 (en) 2022-05-10 2023-05-04 Tetrahydropyrido[3,4-d]pyrimidines compounds as hpk1 inhibitors

Publications (1)

Publication Number Publication Date
IL316818A true IL316818A (en) 2025-01-01

Family

ID=86688794

Family Applications (1)

Application Number Title Priority Date Filing Date
IL316818A IL316818A (en) 2022-05-10 2023-05-04 Tetrahydropyrido[4,3-D]pyrimidine compounds as HPK1 inhibitors

Country Status (9)

Country Link
US (1) US20240025922A1 (enExample)
EP (1) EP4522618A1 (enExample)
JP (1) JP2025521083A (enExample)
CN (1) CN119546610A (enExample)
AU (1) AU2023267747A1 (enExample)
CA (1) CA3250387A1 (enExample)
IL (1) IL316818A (enExample)
TW (1) TW202400612A (enExample)
WO (1) WO2023220541A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025210407A1 (en) * 2024-04-01 2025-10-09 Merck Patent Gmbh (7-{1h,2h,3h-pyrido [2,3-b][1,4]oxazin-7-yl}-5h,6h,7h,8h-pyrido[3,4-d]pyrimidin-2-yl)amine derivatives as bifunctional degraders of hpk1 for the treatment of cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019010302A (es) * 2017-03-30 2019-11-21 Hoffmann La Roche Isoquinolinas como inhibidores de hpk1.

Also Published As

Publication number Publication date
TW202400612A (zh) 2024-01-01
CA3250387A1 (en) 2023-11-16
AU2023267747A1 (en) 2024-11-07
JP2025521083A (ja) 2025-07-08
WO2023220541A1 (en) 2023-11-16
CN119546610A (zh) 2025-02-28
US20240025922A1 (en) 2024-01-25
EP4522618A1 (en) 2025-03-19

Similar Documents

Publication Publication Date Title
US12233062B2 (en) Heterocyclic derivatives useful as SHP2 inhibitors
AU2019240299B2 (en) SHP2 phosphatase inhibitors and methods of use thereof
AU2019334264B2 (en) 5-Morpholin-4-yl-pyrazolo[4,3-b]pyridine derivatives
RU2617405C2 (ru) Пиридоновые и азапиридоновые соединения и способы применения
TW202220994A (zh) 雙環化合物，包含其的藥物組合物及其用途
US20220289753A1 (en) Shp2 inhibitors
CN104125959B (zh) 作为btk活性的抑制剂的杂芳基吡啶酮和氮杂‑吡啶酮化合物
TWI471326B (zh) 作為ｃＦＭＳ抑制劑之經取代之Ｎ－（１Ｈ－吲唑－４－基）咪唑［１，２－ａ］吡啶－３－羧醯胺化合物
KR20180097749A (ko) Rock의 억제제로서의 스피로헵탄 살리실아미드 및 관련 화합물
IL271930B (en) Heterocyclic inhibitors of atr kinase
BR112016016289B1 (pt) Heteroaris e usos dos mesmos
CA2821712A1 (en) Substituted n-(1h-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type iii receptor tyrosine kinase inhibitors
JP7357932B2 (ja) Ｃｒｈｒ２拮抗薬としての縮合環状尿素誘導体
IL323132A (en) DNA polymerase theta inhibitors
TW202246266A (zh) 作為parp7抑制劑的三環衍生物
US20240109900A1 (en) Azabicyclic shp2 inhibitors
US20220306640A1 (en) Hydantoin derivative
JP2023534837A (ja) アンドロゲン受容体モジュレーターとしてのインドール化合物
KR20210100612A (ko) 시클로알칸-1,3-디아민 유도체
KR20240031944A (ko) 암 등의 치료를 위한 shp2 억제제로서의 (s)-1-(5-((피리딘-3-일)티오)피라진-2-일)-4'h,6'h-스피로[피페리딘-4,5'-피롤로[1,2-b]피라졸]-4'-아민 유도체 및 유사 화합물
WO2023220541A1 (en) Tetrahydropyrido[3,4-d]pyrimidines compounds as hpk1 inhibitors
IL316254A (en) Pyrido[D-3,2]pyrimidines and their use as HPK1 inhibitors
TW202610638A (zh) 包含維爾納症候群解旋酶抑制劑之組成物及其使用方法
WO2024153077A1 (zh) Hpk1抑制剂及其制法和用途